| Study to evaluate the safety and pharmacokinetics of inhaled ciprofloxacin in patients with moderate to severe chronic obstructive pulmonary disease (COPD) | |||
| Trial ID: | 13014 | ||
| Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria) | |||
| Indication/Disease: | Pulmonary Disease, Chronic Obstructive | ||
| Status: | Completed Trial Start Date:2009-08-07 |
||
| Phase: | Phase I | ||
| Trial Type: | Interventional Purpose:Treatment, Allocation: Randomized, Masking: Single Blind, Assignment: Parallel Assignment, Number of arms:3, Number of participants: 19 |
||
| Trial Purpose: | Safety Study | ||
| Product: | Cipro (Ciprofloxacin, BAYQ3939) | ||
| Intervention Type: | Drug | ||
| Sponsor:
Collaborators: |
Bayer Schering Pharma AG Novartis Pharmaceuticals Corp. |
||
| Countries: |
|
||
| Key Eligibility Criteria: |
Healthy Volunteers: No Gender :Both Minimum Age :40 Years Maximum Age :75 Years Other inclusion / exclusion criteria may apply. |
||
| Primary outcomes: |
|
||
| Secondary outcomes: |
|
||
| Results/Links | |||
| This information is provided under Bayer Healthcare's for Publication of Clinical Trial Information. Please refer to the Read This First section. © 2006 Bayer HealthCare | |||
 Return to results
New search
Contact for this trial
|
|||
Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Bayer scientific magazine
Clinical trials
Information about clinical studies is available at database of
Company Brochure
